Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 4Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Rectal Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Leucovorin 38Fluorouracil 36Oxaliplatin 34Bevacizumab 34Irinotecan 32Cetuximab 23Capecitabine 18Panitumumab 14IFL protocol 7Folfox protocol 6Celecoxib 6Radiotherapy 5Nivolumab 5Magnetic Resonance Spectroscopy 5Immunohistochemistry 5Gene Expression Profiling 5regorafenib 4pembrolizumab 4dehydroftorafur 4Ramucirumab 4Fluorodeoxyglucose F18 4Floxuridine 4aflibercept 3Surgical Procedures, Operative 3Sorafenib 3Radiosurgery 3Ipilimumab 3Gemcitabine 3Fentanyl 3Drug Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Colonic Neoplasms × CB-839 × Clear all
NCT02861300 2024-12-19

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Case Comprehensive Cancer Center

Phase 1/2 Completed
50 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡